O	0	7	Disease
O	7	8	-
O	8	12	free
O	13	21	survival
O	22	31	advantage
O	32	34	of
O	35	41	weekly
B-intervention	42	52	epirubicin
I-intervention	53	57	plus
I-intervention	58	67	tamoxifen
O	68	74	versus
B-control	75	84	tamoxifen
I-control	85	90	alone
O	91	93	as
O	94	102	adjuvant
O	103	112	treatment
O	113	115	of
O	116	124	operable
O	124	125	,
O	126	130	node
O	130	131	-
O	131	139	positive
O	139	140	,
O	141	148	elderly
O	149	155	breast
O	156	162	cancer
O	163	171	patients
O	171	172	:
O	173	174	6
O	174	175	-
O	175	179	year
O	180	186	follow
O	186	187	-
O	187	189	up
O	190	197	results
O	198	200	of
O	201	204	the
O	205	211	French
O	212	220	adjuvant
O	221	226	study
O	227	232	group
O	233	235	08
O	236	241	trial
O	241	242	.

O	243	245	To
O	246	252	assess
O	253	260	whether
O	261	263	an
O	264	274	epirubicin
O	275	276	(
O	276	279	EPI
O	279	280	)
O	281	282	-
O	282	287	based
O	288	300	chemotherapy
O	301	305	plus
O	306	314	hormonal
O	315	322	regimen
O	323	331	improves
O	332	339	disease
O	339	340	-
O	340	344	free
O	345	346	(
O	346	349	DFS
O	349	350	)
O	351	353	in
O	354	359	women
B-age	360	365	older
I-age	366	370	than
I-age	371	373	65
I-age	374	379	years
O	379	380	,
B-eligibility	381	385	with
I-eligibility	386	390	node
I-eligibility	390	391	-
I-eligibility	391	399	positive
I-eligibility	399	400	,
I-eligibility	401	409	operable
I-eligibility	410	416	breast
I-eligibility	417	423	cancer
I-eligibility	424	425	(
I-eligibility	425	427	BC
I-eligibility	427	428	)
O	428	429	,
O	430	438	relative
O	439	441	to
O	442	451	tamoxifen
O	452	453	(
O	453	456	TAM
O	456	457	)
O	458	463	alone
O	463	464	.

O	465	466	A
O	467	472	total
O	473	475	of
B-total-participants	476	479	338
O	480	488	patients
O	489	493	were
O	494	502	randomly
O	503	511	assigned
O	512	517	after
O	518	525	surgery
O	526	528	to
O	529	536	receive
O	537	540	TAM
O	541	543	30
O	544	546	mg
O	546	547	/
O	547	548	d
O	549	552	for
O	553	554	3
O	555	560	years
O	561	562	(
O	562	565	TAM
O	565	566	,
O	567	568	n
O	569	570	=
B-control-participants	571	574	164
O	574	575	)
O	575	576	,
O	577	579	or
O	580	583	EPI
O	584	586	30
O	587	589	mg
O	590	592	on
O	593	597	days
O	598	599	1
O	599	600	,
O	601	602	8
O	602	603	,
O	604	607	and
O	608	610	15
O	611	616	every
O	617	619	28
O	620	624	days
O	625	628	for
O	629	632	six
O	633	639	cycles
O	640	644	plus
O	645	648	TAM
O	649	651	30
O	652	654	mg
O	654	655	/
O	655	656	d
O	657	660	for
O	661	662	3
O	663	668	years
O	669	670	(
O	670	673	EPI
O	673	674	-
O	674	677	TAM
O	677	678	,
O	679	680	n
O	681	682	=
B-intervention-participants	683	686	174
O	686	687	)
O	687	688	.

O	689	691	In
O	692	696	both
O	697	701	arms
O	701	702	,
O	703	711	patients
O	712	720	received
O	721	733	radiotherapy
O	733	734	,
O	735	744	delivered
O	745	750	after
O	751	763	chemotherapy
O	764	765	(
O	765	767	CT
O	767	768	)
O	769	771	in
O	772	775	the
O	776	779	EPI
O	779	780	-
O	780	783	TAM
O	784	789	group
O	789	790	.

O	791	794	The
B-outcome	795	796	6
I-outcome	796	797	-
I-outcome	797	801	year
I-outcome	802	805	DFS
O	806	811	rates
O	812	816	were
B-cv-bin-percent	817	819	69
I-cv-bin-percent	819	820	.
I-cv-bin-percent	820	821	3
I-cv-bin-percent	821	822	%
O	823	827	with
O	828	831	TAM
O	832	835	and
B-iv-bin-percent	836	838	72
I-iv-bin-percent	838	839	.
I-iv-bin-percent	839	840	6
I-iv-bin-percent	840	841	%
O	842	846	with
O	847	850	EPI
O	850	851	-
O	851	854	TAM
O	855	856	(
O	856	857	P
O	858	859	=
O	860	861	.
O	861	863	14
O	863	864	)
O	864	865	.

O	866	869	The
O	870	882	multivariate
O	883	891	analysis
O	892	897	shows
O	898	899	a
O	900	908	relative
B-outcome	909	913	risk
I-outcome	914	916	of
I-outcome	917	924	relapse
O	925	927	of
O	928	929	1
O	929	930	.
O	930	932	93
O	933	934	(
O	934	936	95
O	936	937	%
O	938	940	CI
O	940	941	,
O	942	943	1
O	943	944	.
O	944	946	70
O	947	949	to
O	950	951	2
O	951	952	.
O	952	954	17
O	954	955	)
O	956	960	with
O	961	964	TAM
O	965	973	compared
O	974	978	with
O	979	982	EPI
O	982	983	-
O	983	986	TAM
O	987	988	(
O	988	989	P
O	990	991	=
O	992	993	.
O	993	996	005
O	996	997	)
O	997	998	.

O	999	1002	The
B-outcome	1003	1004	6
I-outcome	1004	1005	-
I-outcome	1005	1009	year
I-outcome	1010	1012	OS
O	1012	1013	,
O	1014	1021	related
O	1022	1024	to
O	1025	1032	disease
O	1033	1044	progression
O	1044	1045	,
O	1046	1049	was
B-cv-bin-percent	1050	1052	79
I-cv-bin-percent	1052	1053	.
I-cv-bin-percent	1053	1054	1
I-cv-bin-percent	1054	1055	%
O	1056	1059	and
B-iv-bin-percent	1060	1062	79
I-iv-bin-percent	1062	1063	.
I-iv-bin-percent	1063	1064	8
I-iv-bin-percent	1064	1065	%
O	1065	1066	,
O	1067	1079	respectively
O	1080	1081	(
O	1081	1082	P
O	1083	1084	=
O	1085	1086	.
O	1086	1088	41
O	1088	1089	)
O	1089	1090	.

B-outcome	1091	1101	Compliance
O	1102	1106	with
O	1107	1109	CT
O	1110	1113	was
O	1114	1118	good
O	1118	1119	:
O	1120	1122	96
O	1122	1123	.
O	1123	1124	9
O	1124	1125	%
O	1126	1128	of
O	1129	1137	patients
O	1138	1146	received
O	1147	1150	six
O	1151	1157	cycles
O	1157	1158	.

O	1159	1162	The
B-outcome	1163	1168	acute
I-outcome	1169	1177	toxicity
O	1178	1181	per
O	1182	1189	patient
O	1190	1193	was
O	1194	1198	mild
O	1198	1199	:
B-outcome	1200	1205	grade
I-outcome	1206	1207	2
I-outcome	1208	1219	neutropenia
O	1220	1222	in
O	1223	1224	5
O	1224	1225	.
O	1225	1226	9
O	1226	1227	%
O	1227	1228	,
B-outcome	1229	1234	grade
I-outcome	1235	1236	2
I-outcome	1237	1243	anemia
O	1244	1246	in
O	1247	1248	2
O	1248	1249	.
O	1249	1250	0
O	1250	1251	%
O	1251	1252	,
B-outcome	1253	1258	grade
I-outcome	1259	1260	3
I-outcome	1261	1267	nausea
I-outcome	1268	1270	or
I-outcome	1271	1279	vomiting
O	1280	1282	in
O	1283	1284	4
O	1284	1285	.
O	1285	1286	6
O	1286	1287	%
O	1287	1288	,
O	1289	1292	and
B-outcome	1293	1298	grade
I-outcome	1299	1300	3
I-outcome	1301	1309	alopecia
O	1310	1312	in
O	1313	1314	7
O	1314	1315	.
O	1315	1316	2
O	1316	1317	%
O	1317	1318	.

O	1319	1323	Five
O	1324	1329	cases
O	1330	1331	(
O	1331	1333	in
O	1334	1338	five
O	1339	1347	patients
O	1347	1348	)
O	1349	1351	of
B-outcome	1352	1361	decreased
I-outcome	1362	1366	left
I-outcome	1367	1378	ventricular
I-outcome	1379	1387	ejection
I-outcome	1388	1396	fraction
O	1397	1405	occurred
O	1406	1411	after
O	1412	1414	CT
O	1414	1415	:
O	1416	1421	three
O	1422	1427	after
O	1428	1436	adjuvant
O	1437	1439	CT
O	1439	1440	,
O	1441	1444	and
O	1445	1448	two
O	1449	1454	after
O	1455	1468	anthracycline
O	1468	1469	-
O	1469	1474	based
O	1475	1477	CT
O	1478	1481	for
O	1482	1489	relapse
O	1489	1490	.

O	1491	1494	One
O	1495	1502	patient
B-outcome	1503	1507	died
I-outcome	1508	1510	as
I-outcome	1511	1512	a
I-outcome	1513	1519	result
I-outcome	1520	1522	of
I-outcome	1523	1534	dysrhythmia
O	1535	1542	related
O	1543	1545	to
O	1546	1559	carcinomatous
O	1560	1572	lymphangitis
O	1572	1573	.

O	1574	1576	No
B-outcome	1577	1586	secondary
I-outcome	1587	1595	leukemia
O	1596	1604	occurred
O	1604	1605	.

O	1606	1610	This
O	1611	1616	study
O	1617	1626	conducted
O	1627	1629	in
O	1630	1634	node
O	1634	1635	-
O	1635	1643	positive
O	1644	1651	elderly
O	1652	1660	patients
O	1661	1673	demonstrates
O	1674	1675	a
O	1676	1687	significant
O	1688	1700	contribution
O	1701	1703	of
O	1704	1705	a
O	1706	1712	weekly
O	1713	1716	EPI
O	1717	1724	regimen
O	1725	1727	in
O	1728	1733	terms
O	1734	1736	of
O	1737	1740	DFS
O	1740	1741	.

O	1742	1750	Moreover
O	1750	1751	,
O	1752	1756	this
O	1757	1764	regimen
O	1765	1767	is
O	1768	1772	safe
O	1773	1776	for
O	1777	1788	hematologic
O	1788	1789	,
O	1790	1804	nonhematologic
O	1804	1805	,
O	1806	1809	and
O	1810	1817	cardiac
O	1818	1828	toxicities
O	1828	1829	.
